<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30231328</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>20</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1548-8756</ISSN>                <JournalIssue CitedMedium="Internet">                    <Issue>38</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>May</Month>                        <Day>23</Day>                    </PubDate>                </JournalIssue>                <Title>American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting</Title>                <ISOAbbreviation>Am Soc Clin Oncol Educ Book</ISOAbbreviation>            </Journal>            <ArticleTitle>Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>65-77</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1200/EDBK_200715</ELocationID>            <Abstract>                <AbstractText>Metastatic breast cancer continues to be a life-threatening diagnosis that impacts hundreds of thousands of patients around the world. Targeted therapies are usually associated with less toxicity compared with cytotoxic chemotherapies and often induce response or durable disease control in estrogen receptor (ER) and/or HER2+ breast cancers. Drugs that target CDK 4/6 either alone or in combination with endocrine therapy have demonstrated substantial improvements in progression-free survival (PFS) compared with endocrine monotherapy. Most recently, PARP inhibitors have shown longer PFS compared with physician's choice of chemotherapy in BRCA-associated cancers, leading to the first U.S. Food and Drug Administration (FDA) approval of a targeted therapy with the potential to benefit a subgroup of patients with triple-negative breast cancer (TNBC). Finally, newer drug delivery strategies using antibody drug conjugates have also allowed a &quot;targeted approach&quot; to deliver moderate to extremely potent cytotoxins directly to sites of metastatic disease, with less toxicity.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Pegram</LastName>                    <ForeName>Mark D</ForeName>                    <Initials>MD</Initials>                    <AffiliationInfo>                        <Affiliation>From the Stanford Comprehensive Cancer, Stanford, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Mayo Clinic Cancer Center, Rochester, MN.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zong</LastName>                    <ForeName>Yu</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>From the Stanford Comprehensive Cancer, Stanford, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Mayo Clinic Cancer Center, Rochester, MN.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yam</LastName>                    <ForeName>Clinton</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>From the Stanford Comprehensive Cancer, Stanford, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Mayo Clinic Cancer Center, Rochester, MN.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Goetz</LastName>                    <ForeName>Matthew P</ForeName>                    <Initials>MP</Initials>                    <AffiliationInfo>                        <Affiliation>From the Stanford Comprehensive Cancer, Stanford, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Mayo Clinic Cancer Center, Rochester, MN.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Moulder</LastName>                    <ForeName>Stacy L</ForeName>                    <Initials>SL</Initials>                    <AffiliationInfo>                        <Affiliation>From the Stanford Comprehensive Cancer, Stanford, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Mayo Clinic Cancer Center, Rochester, MN.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Am Soc Clin Oncol Educ Book</MedlineTA>            <NlmUniqueID>101233985</NlmUniqueID>            <ISSNLinking>1548-8748</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30231328</ArticleId>            <ArticleId IdType="doi">10.1200/EDBK_200715</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>